Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.243
Buy
RSI(14)
62.644
Neutral
STOCH(KDJ)(9,3,3)
84.517
Overbought
ATR(14)
1.480
High Vlolatility
CCI(14)
147.126
Buy
Williams %R
14.340
Overbought
TRIX(12,20)
0.757
Sell
StochRSI(14)
53.739
Sell
Search
Vor Biopharma Inc
VORAdd to Watchlist
21.150USD
-0.650-2.98%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.15BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-2.98%
5 Days
+9.81%
1 Month
+2.72%
6 Months
+65.36%
Year to Date
+61.70%
1 Year
-49.64%
Key Figures
21.510Open
21.720High
905.01KVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.67%Turnover Ratio
21.800Prev. Close
20.480Low
13.31MTurnover
LossP/E Static
-7.62P/B
0.00%Div Yield TTM
-286.69%ROA
65.80052wk High
1.00Volume Ratio
-116.91MNet Profit
54.19MShares
-70.4017EPS TTM
1.72Beta
-125.43%ROE
3.38452wk Low
5.69%Amplitude
--Gross Margin
1.15BMarket Cap
1.36Reward/Risk
6.21%Risk Rate
Vor Biopharma Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
37.875
Target Price
+79.08%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Vor Biopharma Inc
VOR
9
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
20.388
Buy
MA10
19.719
Buy
MA20
19.332
Buy
MA50
16.746
Buy
MA100
15.863
Buy
MA200
15.521
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Vor Biopharma Inc Info
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.
Ticker SymbolVOR
CompanyVor Biopharma Inc
CEOKress (Jean-Paul)
Websitehttps://www.vorbio.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52790.700
+412.700 (+0.79%)
28508.900
+348.000 (+1.24%)
7535.100
+60.000 (+0.80%)
14624.000
-125.000 (-0.85%)
63605.000
+753.000 (+1.20%)
6405.700
+40.300 (+0.63%)
78.522
-7.412 (-8.63%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4056.970
+15.540 (+0.39%)
FAQs
What is the current price of Vor Biopharma Inc (VOR)?
The current price of Vor Biopharma Inc (VOR) is 21.15.
What is the symbol of Vor Biopharma Inc?
The ticker symbol of Vor Biopharma Inc is VOR.
What is the 52-week high of Vor Biopharma Inc?
The 52-week high of Vor Biopharma Inc is 65.80.
What is the 52-week low of Vor Biopharma Inc?
The 52-week low of Vor Biopharma Inc is 3.38.
What is the market capitalization of Vor Biopharma Inc?
The market capitalization of Vor Biopharma Inc is 1.15B.
Is Vor Biopharma Inc (VOR) currently rated as Buy, Hold, or Sell?
According to analysts, Vor Biopharma Inc (VOR) has an overall rating of Buy, with a price target of 37.88.
What is the Earnings Per Share (EPS TTM) of Vor Biopharma Inc (VOR)?
The Earnings Per Share (EPS TTM) of Vor Biopharma Inc (VOR) is -70.50.